News & Publications

December 1, 2021

Just Announced: Entos to receive $15.5M from AB gov't for vaccine manufacturing facility in Edmonton!

Published by:

Perrin H Beatty

November 16, 2021

BioAlberta 2020 Company of the Year to... Entos Pharmaceuticals!

Published by:

November 15, 2021

Entos Enters Agreement with BioMarin to Formulate Product Candidates Incorporating Fusogenix PLVs

Published by:

Perrin Beatty

September 7, 2021

Entos’ COVID-19 DNA Vaccine Candidate Approved for Phase 2 Clinical Trial in South Africa

Published by:

Perrin Beatty

July 7, 2021

Canadian Companies Entos Pharmaceuticals and Montrium Join Forces to Drive Clinical Innovation

Published by:

Perrin Beatty

May 18, 2021

Recruitment Update for the Phase 1 Clinical Trial of Entos’ Made in Canada DNA Vaccine for COVID-19

Published by:

Perrin Beatty

April 15, 2021

April 15 Marks Start of Phase I trial of Entos' COVID-19 DNA Vaccine with First Recruits

Published by:

Perrin Beatty

March 30, 2021

Made-in-Alberta COVID-19 vaccine candidate headed for clinical trials

Published by:

Entos Pharmaceuticals

February 25, 2021

Entos Partners with ACTM and the Ottawa Hospital's BMC to Manufacture and Ready its COVID-19 DNA Vaccine for Clinical Trials

Published by:

Perrin Beatty

November 9, 2020

Propel(x) Presents: The Path to a COVID-19 Vaccine Dec 11, 9 am PT

Published by:

Perrin Beatty

March 18, 2020

Entos Pharmaceuticals Is Developing a DNA Vaccine Against COVID-19 Using Its Fusogenix Nanomedicine Platform

Published by:

Entos Pharmaceuticals

December 20, 2019

HICKS ON BIZ: The University of Alberta’s next big thing

Published by:

Graham Hicks

October 1, 2019

IPA and Entos to Collaborate on Immuno-oncology Discovery Research

Published by:

Entos

November 1, 2018

Entos Pharmaceuticals joins JLABS San Diego

Published by:

Entos Pharmaceuticals

July 2, 2018

Entos awarded entry into the Merck Invention Accelerator

Published by:

Entos Pharmaceuticals

March 30, 2018

Entos and Oisin Bio Announce Fusogenix License for SENSOlytics™

Published by:

Entos Pharmaceuticals

June 26, 2018

Entos and Oisin Bio Launch OncoSenX: A Spinoff Company Targeting Cancer

Published by:

John D. Lewis, PhD

November 13, 2018

Precision Nanosystems and Entos Pharmaceuticals sign license agreement

Published by:

PRESS RELEASE (Precision NanoSystems)

Entos Pharmaceuticals
Unit 4550, 10230 Jasper Avenue
Edmonton, Alberta, Canada
T5J 4P6

Email: info@entospharma.com

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.